| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.8 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.8 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | shikonin | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |